openPR Logo
Press release

Protagen and GeneBio Sign Distribution Agreement for Modiro®

05-29-2008 03:10 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Protagen AG

/ PR Agency: Dr. Holger Bengs Biotech Consulting
Dortmund, Germany and Geneva, Switzerland – May 29, 2008 - Protagen AG and Geneva Bioinformatics (GeneBio) SA today announced a distribution agreement that allows GeneBio to distribute Protagen’s Modiro, a novel software tool enabling rapid and automated detection of true post-translational modifications in MS/MS datasets.

Under the terms of the agreement, GeneBio will distribute the Modiro package on a global basis; at the same time, GeneBio and Protagen will collaborate closely in order to seamlessly link the Modiro functionalities to GeneBio’s Phenyx software platform for MS data analysis.

Post-translational protein modifications modulate the activity of many proteins and the in-depth analysis of these changes is of growing importance in the research and development of new drug candidates. Modiro enables researchers to identify significantly more of these crucial modifications using existing mass-spectrometry data. In addition, the automated identification of PTMs by Modiro significantly reduces time and efforts in protein analysis.

Developed in collaboration with the Swiss Institute of Bioinformatics (SIB), Phenyx is GeneBio’s renowned software platform for the identification and characterization of proteins and peptides from mass spectrometry data. The Phenyx platform is specifically designed to meet the concurrent demands of high-throughput MS data analysis and dynamic results assessment via a customisable architecture and an innovative user friendly interface (http://phenyx.vital-it.ch/pwi).

“We are very excited about this collaboration with GeneBio and believe it will help to bring Modiro to wide range of new customers,” said Dr. Christoph Hüls, CEO of Protagen. “We are well aware of the reputation of both GeneBio and Phenyx within the industry and feel that our combined efforts will help to establish Modiro as the gold-standard for PTM analysis. In addition, we look forward to working with the GeneBio team in order to enhance both the Modiro and Phenyx platform.”

“We are pleased to be able to distribute Modiro and work with Protagen to help raise the bar in our industry,” said Nasri Nahas, CEO of GeneBio. “The addition of Modiro to our product line-up and the eventual technological gains that our companies will share through this cooperation will bring us closer to our goal of providing the most comprehensive platform in the MS field. Phenyx has seen significant traction in the market since its inception; working with Protagen will build and extend our expertise, thereby bringing us closer to our goals.”

For more information concerning this distribution agreement, for Phenyx or Modiro product demonstrations, please visit GeneBio booth #27 at the upcoming ASMS Conference on Mass Spectrometry in Denver, Colorado, from June 1-5.

Contact
Protagen AG
Dr. Christoph Hüls
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Germany
Tel: +49 (0) 231 9742 6300
E-Mail: info@protagen.de

GeneBio
Andrew Smith
Marketing Manager
Geneva Bioinformatics S.A.
25 avenue de Champel
1206 Genf
Switzerland
Tel: +41 (0) 22 702 9900
E-Mail: andrew.smith@genebio.com

Media enquiries:
Dr. Holger Bengs
Biotech Consulting
Tel: +49 (0) 69 6199 4273
E-Mail: info@holgerbengs.de

About Protagen AG
Protagen (www.protagen.com) is a leading provider of products, services and software solutions for protein research. Operating internationally to provide customers with products and services of the highest quality, Protagen has offices in Dortmund, Germany and New Jersey, USA. The Company has a decade of experience in applying the most advanced protein research tools and techniques to improve the efficiency of the drug discovery and development process.
As an innovator in protein biochips, Protagen has developed UNIclone®, a patent protected platform for protein expression libraries and protein arrays, and UNIchip®, a versatile and highly efficient series of protein biochip products for antibody development. In addition, it has established UNIarrayTM, a highly efficient technology platform for biomarker discovery on an industrial scale.

About GeneBio
Geneva Bioinformatics (GeneBio) SA is a leading bioinformatics company providing the life science community with world-class proteomics software that bridges the gap between information gathering and knowledge generation. Established in 1997, we focus our expertise on protein identification and characterization as well as proteome imaging, offering clients and partners a high degree of specialization essential to proteomics research. Close ties to academic peers and a thorough network of distribution and strategic partners give us both unfettered access to scientific excellence and recognized market presence so that we may best serve the scientific community. For more information about GeneBio, please visit: www.genebio.com.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Protagen and GeneBio Sign Distribution Agreement for Modiro® here

News-ID: 45757 • Views: 1121

More Releases from Protagen AG

Protagen and Charles River form strategic partnership
Dortmund, Germany, October 28, 2011. Protagen AG, Dortmund, a GMP-certified specialist in the characterization of protein drugs and Charles River Laboratories International, Inc., one of the world leading companies in high-quality research models and preclinical and clinical support services, are pleased to announce a strategic Marketing & Sales alliance. For Charles River Biopharmaceutical Services (BPS) the fast-growing demand for biopharmaceuticals testing requires an expert partner with a broad range
Protagen and OncoTyrol form strategic alliance to validate the UNIarray® techno …
Dortmund, Germany and New Jersey, USA, June 10, 2009. Protagen AG and the Medical University Innsbruck, Department of Urology, have recently identified autoantigen candidates present in serum of patients with prostate cancer using the proprietary UNIArray® technology platform. In Europe, prostate cancer is the second most frequent lethal malignancy in men. Yearly about 40,000 men die of prostate cancer in the European Union. Current standard of screening for prostate
Protagen meets with FDA
Dortmund, Germany and New Jersey, USA, February 19, 2009. Protagen AG, a leading provider of GMP compliant protein analytical services, protein bioinformatics, and protein biochips announces that it participated in two meetings with FDA personnel during the week of January 26, 2009. The meetings were intended to provide a detailed introduction to the company’s UNIarray® technology position and its potential use in the development of novel diagnostics for multiple sclerosis
Bayer HealthCare and Protagen sign a contract to evaluate the UNIarray® technol …
Dortmund, Germany and New Jersey, USA, December 3, 2008. Protagen AG announces the closing of a cooperation contract with Bayer HealthCare AG, Leverkusen, Germany, about the evaluation of the UNIarray® technology for discovery of novel biomarkers in atrial fibrillation. Bayer HealthCare is currently investigating atrial fibrillation after heart surgery in a clinical study. A certain number of patients develop this type of cardiac symptoms after surgery. Currently, it is not possible

All 5 Releases


More Releases for GeneBio

Asia-Pacific Bioinformatics market is anticipated to grow at a CAGR of 17% durin …
The demand for bioinformatics is surging due to its escalating application in agriculture, medical, animal biotechnology, increasing advancement in the technology and increasing investment in research and development (R&D) process for drug discovery are the driving factors for the growth of the Asia-Pacific Bioinformatics market. Besides this, robust growth of proteomics and genomics, rising demand for personalized medicine and clinical diagnostics along surging spending on healthcare infrastructure are the factors
Bioinformatics Market projected to reach $18,233.00 million by 2025, growing at …
The New Report "Bioinformatics Market" published by Premium Market Insights, covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. The global bioinformatics market generated $6,389.00 million in 2017, and is projected to reach $18,233.00 million by 2025, growing at a CAGR of 13.8% from 2018 to 2025 Bioinformatics is the combination of information technology, statistics,
Rapid RNA Testing Kit Market Outlook by Trend, Regional Demand, Product, and For …
The comprehensive research and analysis report comes out as an incredible and a must-have resource for global Rapid RNA Testing Kit industry players to gain a competitive edge over their opponents. It includes reliable and verified industry size, CAGR, production, consumption, and sales forecasts for the global Rapid RNA Testing Kit industry. It also provides industry revenue and volume estimates for years up to 2026. Readers of the report can
Rapid RNA Testing Kit Market Insights and Global Outlook During 2020 to 2026; Ge …
The Market Insights Reports has published a report titled global Rapid RNA Testing Kit Market research report 2020 that is a detailed observation of several aspects, including the rate of growth, technological advances and different methodologies implemented by the primary current market players. The report is based on a collective analysis of data, which is obtained through primary and secondary research. It provides a systematic approach to the current and
Bioinformatics Market 2020 Industry Research Growth Opportunities by Regions, Ty …
Bioinformatics Market 2020 Industry report gives a comprehensive account of the Global Bioinformatics market. Details such as the size, key players, segmentation, SWOT analysis, most influential trends, and business environment of the market are mentioned in this report. Furthermore, this report features tables and figures that render a clear perspective of the Bioinformatics market. Bioinformatics Market has accounted for USD 2.8 billion in 2016 and is expected to reach USD 7.69
Bioinformatics Industries Survey Research Forecasting CAGR of 16.8% with Product …
Global bioinformatics market is expected to reach USD 22.78 billion by 2024 from USD 6.54 billion in 2016, at a CAGR of 16.8% in the forecast period 2017 to 2024. The new market report contains data for historic years 2014 & 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024. Get Free Sample Research Report: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-bioinformatics-market The global bioinformatics market is expected to